Curis. has filed a patent for methods of treating IRAK4 associated diseases and disorders. The patent also covers pharmaceutical compositions containing compounds for treating these conditions. The claim specifies that the method involves administering 25 – 500 mg of a compound (Compound 1) or its pharmaceutically acceptable salt to the subject in need. GlobalData’s report on Curis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Curis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Curis, Cancer treatment biomarkers was a key innovation area identified from patents. Curis's grant share as of September 2023 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Treating diseases and disorders using compound 1

Source: United States Patent and Trademark Office (USPTO). Credit: Curis Inc

A recently filed patent (Publication Number: US20230310444A1) describes a method for treating various diseases and disorders using a specific compound (referred to as Compound 1) or a pharmaceutically acceptable salt thereof. The patent claims cover different aspects of the treatment method, including the dosage range, combination therapy with other inhibitors, and administration routes.

The method involves administering 25 - 500 mg of Compound 1 to a subject in need of treatment. The diseases and disorders that can be treated using this method include those associated with IRAK4 and those resistant to treatment with a BTK inhibitor. The diseases and disorders mentioned range from various types of cancers, such as non-Hodgkin's lymphoma and leukemia, to inflammatory diseases and disorders like autoimmune diseases and graft vs host disease.

In some cases, the method involves conjointly administering Compound 1 with a BTK inhibitor or a BCL-2 inhibitor. Specific inhibitors mentioned include ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebrutinib, and HM7 1224. The method also includes conjointly administering Compound 1 with a BCL-2 inhibitor called ventoclax.

The dosage of Compound 1 can vary depending on the specific disease or disorder being treated. The patent claims cover a wide range of dosage options, from 25 mg to 500 mg, and suggest different administration frequencies, such as once or twice per day. The patent also mentions specific dosages for the BTK inhibitors and the BCL-2 inhibitor ventoclax.

The patent also describes a pharmaceutical composition comprising Compound 1 and a pharmaceutically acceptable excipient. The composition can be in the form of a tablet or a capsule, and the patent provides details on the formulation, including the use of diluents, binders, surfactants, and lubricants.

Overall, the patent claims provide a comprehensive method for treating various diseases and disorders using Compound 1 or its pharmaceutically acceptable salt. The method covers different dosage ranges, combination therapies, and administration routes, offering potential options for personalized treatment approaches.

To know more about GlobalData’s detailed insights on Curis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies